NkartaNKTX
Market Cap: $417M
About: Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Employees: 150
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
215% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $479K
189% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
7% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 27
2% less funds holding
Funds holding: 113 [Q1] → 111 (-2) [Q2]
35.01% less ownership
Funds ownership: 128.98% [Q1] → 93.97% (-35.01%) [Q2]
43% less capital invested
Capital invested by funds: $689M [Q1] → $391M (-$297M) [Q2]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
HC Wainwright & Co. Emily Bodnar 30% 1-year accuracy 32 / 108 met price target | 272%upside $22 | Buy Maintained | 15 Aug 2024 |
Needham Gil Blum 46% 1-year accuracy 64 / 138 met price target | 120%upside $13 | Buy Reiterated | 14 Aug 2024 |
Raymond James Laura Prendergast 50% 1-year accuracy 3 / 6 met price target | 171%upside $16 | Strong Buy Upgraded | 14 Aug 2024 |
HC Wainwright & Co. Emily Bodnar 30% 1-year accuracy 32 / 108 met price target | 289%upside $23 | Buy Reiterated | 24 Jul 2024 |
Needham Gil Blum 46% 1-year accuracy 64 / 138 met price target | 120%upside $13 | Buy Reiterated | 28 Jun 2024 |
Financial journalist opinion
Based on 5 articles about NKTX published over the past 30 days